Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

November
02
2017

Sensus Healthcare Reports Third Quarter Financial Results Featuring Revenue up 44%

Marks eighth consecutive quarter of double-digit year-over-year revenue growth Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 2, 2017 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing…

November
01
2017

Sensus Healthcare Launches SRT-100 in China for Keloid Prevention and Treatment at Major Dermatology Conference, Extends Distribution Agreement with Chindex Medical

BOCA RATON, Fla., Nov. 1, 2017 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces it has…

October
31
2017

The Latest Treatment Option for Non-Melanoma Skin Cancers

The Incidence of Non-Melanoma Skin Cancer in the United States Skin cancer is the most common form of cancer in the United States. Did you know it is currently estimated that one in five Americans…

October
31
2017

Sensus Healthcare Announces Clearance to Market the SRT-100™ in Mexico

BOCA RATON, Fla., Oct. 31, 2017 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that the…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy